```
=> s l3
L4            4 L3

=> d abs fbib fhitstr 1-4

L4   ANSWER 1 OF 4  CAPLUS  COPYRIGHT 2009 ACS on STN
AB   Aqueous gel formulations, including an immune response modifier (IRM), such as
     those chosen from imidazoquinoline amines, tetrahydroimidazoquinoline
     amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine
     amines, 1,2 -bridged imidazoquinoline amines, imidazonaphthyridine amines,
     imidazotetrahydronaphthyridine amines, oxazoloquinoline amines,
     thiazoloquinoline amines, oxazolopyridine amines, thiazolopyridine amines,
     oxazolonaphthyridine amines, thiazolonaphthyridine amines,
     pyrazolopyridine amines, pyrazoloquinoline amines,
     tetrahydropyrazoloquinoline amines, pyrazolonaphthyridine amines,
     tetrahydropyrazolonaphthyridine amines, and 1 H-imidazo dimers fused to
     pyridine amines, quinoline amines, tetrahydroquinoline amines,
     naphthyridine amines, or tetrahydronaphthyridine amines, are provided.
     Methods of use and kits are also provided.  For example, gel was prepared
     containing 4-(4-amino-2-propyl-1H-imidazo[4,5-c]quinolin-1-yl)-N-
     propylbutyramide 0.1%, 0.25N ethanesulfonic acid 0.594%, Carbomer 974P
     2.1%, propylene glycol 15%, methylparaben 0.15%, propylparaben 0.03%,
     edetate disodium 0.05%, 20% tromethamine solution 1.5% and purified water
     80.48%.
AN   2006:795800  CAPLUS
DN   145:235790
TI   Aqueous gel formulations containing immune response modifiers
IN   Ma, David Q.; Perman, Christopher S.; Skwierczynski, Raymond D.
PA   3M Innovative Properties Company, USA
SO   PCT Int. Appl., 123pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.          DATE
     ---------------     ----   --------    --------------------     --------
PI   WO 2006084251       A2     20060810    WO 2006-US4201           20060203
     WO 2006084251       A3     20070405
          W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
              CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
              GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,
              KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,
              MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,
              SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,
              VN, YU, ZA, ZM, ZW
          RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
              IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
              CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
              GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
              KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA
                                          US 2005-650030P     P  20050204
     AU 2006210392       A1     20060810    AU 2006-210392          20060203
                                          US 2005-650030P     P  20050204
                                          WO 2006-US4201      W  20060203
```

CA 2597092	A1	20060810	CA 2006-2597092	20060203
			US 2005-650030P	P 20050204
			WO 2006-US4201	W 20060203
EP 1844201	A2	20071017	EP 2006-720400	20060203
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
			US 2005-650030P	P 20050204
			WO 2006-US4201	W 20060203
JP 2008530022	T	20080807	JP 2007-554306	20060203
			US 2005-650030P	P 20050204
			WO 2006-US4201	W 20060203
US 20090163532	A1	20090625	US 2008-883665	20080819
			US 2005-650030P	P 20050204
			WO 2006-US4201	W 20060203

IT 866649-05-0
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(aqueous gel formulations containing immune response modifiers)
RN 866649-05-0 CAPLUS
CN 1H-Imidazo[4,5-c]quinoline-1-butanamide, 4-amino-N,2-dipropyl- (CA INDEX NAME)



L4 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN
GI



AB Title compds. I [R1 = amide linked via alkyl, alkylene, or alkylalkylene; R2 = H or a non-interfering substituent; R3 and R4 independently = H, halo, alkyl, alkoxy, etc.], pharmaceutical compns. containing the compds., intermediates, and methods of making and methods of use of these compds. as immunomodulators, for modulating cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed. Thus, e.g., II was prepared by amidation of Et 4-(2-propyl-1H-imidazo[4,5-c]quinolin-1-yl)butanoate (preparation given) with morpholine and subsequent oxidation/amination. Methods are described for assaying cytokine induction (no data).

AN 2005:1103493 CAPLUS

DN 143:387036

TI Preparation of amide-substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines

IN Krepski, Larry R.; Dellaria, Joseph F., Jr.; Duffy, Daniel E.; Amos, David T.; Zimmermann, Bernhard M.; Moser, William H.

PA 3M Innovative Properties Company, USA

SO PCT Int. Appl., 234 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005094531	A2	20051013	WO 2005-US9880	20050324
	WO 2005094531	A3	20060309		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				US 2004-555753P	P 20040324
				US 2004-578769P	P 20040610
	AU 2005228150	A1	20051013	AU 2005-228150	20050324
				US 2004-555753P	P 20040324
				US 2004-578769P	P 20040610
				WO 2005-US9880	W 20050324
	CA 2559863	A1	20051013	CA 2005-2559863	20050324
				US 2004-555753P	P 20040324
				US 2004-578769P	P 20040610
				WO 2005-US9880	W 20050324
	EP 1730143	A2	20061213	EP 2005-731309	20050324
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
				US 2004-555753P	P 20040324
				US 2004-578769P	P 20040610
				WO 2005-US9880	W 20050324
	JP 2007530579	T	20071101	JP 2007-505186	20050324
				US 2004-578769P	P 20040610

				WO 2005-US9880	W	20050324
US 20070219196	A1	20070920	US 2006-599159			20060921
			US 2004-555753P	P		20040324
			US 2004-578769P	P		20040610
			WO 2005-US9880	W		20050324
IN 2006CN03484	A	20070615	IN 2006-CN3484			20060922
			US 2004-555753P	P		20040324
			WO 2005-US9880	W		20050324

OS CASREACT 143:387036; MARPAT 143:387036

IT 1026064-56-1
RL: PRPH (Prophetic)
(Preparation of amide-substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines)

RN 1026064-56-1 CAPLUS

CN 1H-Imidazo[4,5-c]quinoline-1-propanamide, 4-amino-6,7,8,9-tetrahydro-2-methyl- (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN

GI



I



II

AB Title compds. {I; X = alkylene optionally interrupted by one or more -O-; Z = C:O, - C(:O)O-, -C(OR3)2-; R1 = H, (un)substituted alkyl, alkylene/aryl, alkylene/heteroaryl; Q = O, S; R3 = (un)substituted alkyl, alkylene/aryl, alkylene/heteroaryl; R2 = H, (un)substituted alk(en/yn)yl, hetero/aryl, alkylenealkyl, etc.; RA, RB = independently H, halo, alk(en)yl, alkoxy, alkylthio, NH2 and derivs.; or RACCRB = (un)substituted fused aryl ring or fused 5-7-membered saturated ring; and their pharmaceutically acceptable salts}, were prepared as immunomodulators for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases. For example, II was prepared by reacting 4-(2-Butyl-1H-imidazo[4,5-c]quinolin-1-yl)butyraldehyde (preparation given) with MeMgBr, followed by oxidation, reductive amination of the ketone, oxidation with m-CPBA/reaction with NH4OH. I have been found to induce cytokine biosynthesis by inhibiting production of tumor necrosis factor TNF-α when tested on an in vitro human blood cell system (no data).

AN 2005:490270 CAPLUS

DN 143:26611

TI Preparation of oxime substituted imidazo-containing compounds, particularly imidazoquinolines, as inducers of cytokine biosynthesis for treatment of viral and neoplastic diseases

IN Krepski, Larry R.; Dellaria, Joseph F., Jr.; Duffy, Daniel E.; Radmer, Matthew R.; Amos, David T.

PA 3M Innovative Properties Company, USA

SO PCT Int. Appl., 200 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005051317	A2	20050609	WO 2004-US39512	20041124
WO 2005051317	A3	20060511		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

				US 2003-524961P	P	20031125
				US 2004-580139P	P	20040616
AU 2004293078	A1	20050609		AU 2004-293078		20041124
				US 2003-524961P	P	20031125
				US 2004-580139P	P	20040616
				WO 2004-US39512	W	20041124
CA 2547020	A1	20050609		CA 2004-2547020		20041124
				US 2003-524961P	P	20031125
				US 2004-580139P	P	20040616
				WO 2004-US39512	W	20041124
EP 1687307	A2	20060809		EP 2004-812098		20041124
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS						
				US 2003-524961P	P	20031125
				US 2004-580139P	P	20040616
				WO 2004-US39512	W	20041124
BR 2004016936	A	20070116		BR 2004-16936		20041124
				US 2003-524961P	P	20031125
				US 2004-580139P	P	20040616
				WO 2004-US39512	W	20041124
CN 1926138	A	20070307		CN 2004-80040954		20041124
				US 2003-524961P	P	20031125
				US 2004-580139P	P	20040616
				WO 2004-US39512	W	20041124
JP 2007512370	T	20070517		JP 2006-541697		20041124
				US 2003-524961P	P	20031125
				US 2004-580139P	P	20040616
				WO 2004-US39512	W	20041124
SG 148201	A1	20081231		SG 2008-8728		20041124
				US 2003-524961P	P	20031125
				US 2004-580139P	P	20040616
MX 2006005910	A	20060823		MX 2006-5910		20060524
				US 2003-524961P	P	20031125
				US 2004-580139P	P	20040616
				WO 2004-US39512	W	20041124
IN 2006CN01848	A	20070608		IN 2006-CN1848		20060525
				US 2003-524961P	P	20031125
				WO 2004-US39512	W	20041124
KR 2006125818	A	20061206		KR 2006-712734		20060623
				US 2003-524961P	P	20031125
				US 2004-580139P	P	20040616
				WO 2004-US39512	W	20041124
ZA 2006005216	A	20070425		ZA 2006-5216		20060623
				US 2003-524961P	P	20031125

PATENT FAMILY INFORMATION:
FAN 2005:493478

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005051324	A2	20050609	WO 2004-US39673	20041124
	WO 2005051324	A3	20060105		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				US 2003-524961P	P 20031125
				US 2004-580139P	P 20040616
				US 2004-581293P	P 20040618
	AU 2004293096	A1	20050609	AU 2004-293096	20041124
				US 2003-524961P	P 20031125
				US 2004-580139P	P 20040616
				US 2004-581293P	P 20040618
				WO 2004-US39673	W 20041124
	CA 2547085	A1	20050609	CA 2004-2547085	20041124
				US 2003-524961P	P 20031125
				US 2004-580139P	P 20040616
				US 2004-581293P	P 20040618
				WO 2004-US39673	W 20041124
	EP 1686992	A2	20060809	EP 2004-812235	20041124
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
				US 2003-524961P	P 20031125
				US 2004-580139P	P 20040616
				US 2004-581293P	P 20040618
				WO 2004-US39673	W 20041124
	CN 1905874	A	20070131	CN 2004-80040953	20041124
				US 2003-524961P	P 20031125
				US 2004-580139P	P 20040616
				US 2004-581293P	P 20040618
				WO 2004-US39673	W 20041124
	JP 2007512349	T	20070517	JP 2006-541442	20041124
				US 2003-524961P	P 20031125
				US 2004-580139P	P 20040616
				US 2004-581293P	P 20040618
				WO 2004-US39673	W 20041124
	US 20070099901	A1	20070503	US 2006-595859	20060518
				US 2003-524961P	P 20031125
				US 2004-580139P	P 20040616
				US 2004-581293P	P 20040618
				WO 2004-US39673	W 20041124
	IN 2006CN01847	A	20070608	IN 2006-CN1847	20060525
				US 2003-524961P	P 20031125
				WO 2004-US39673	W 20041124
	ZA 2006005216	A	20070425	ZA 2006-5216	20060623
				US 2003-524961P	P 20031125
OS	CASREACT 143:26611; MARPAT 143:26611				

IT 845638-60-0P, 4-(4-Amino-2-propyl-1H-imidazo[4,5-c]quinolin-1-yl)-N-methoxy-N-methylbutyramide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of oxime substituted imidazoquinolines as inducers of cytokine biosynthesis for treatment of viral and neoplastic disease)
RN 845638-60-0 CAPLUS
CN 1H-Imidazo[4,5-c]quinoline-1-butanamide, 4-amino-N-methoxy-N-methyl-2-propyl- (CA INDEX NAME)



OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN
AB Pharmaceutical formulations in an aqueous (preferably, sprayable) formulation including an immune response modifier (IRM), such as those chosen from imidazoquinoline amines, tetrahydroimidazoquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, 1,2-bridged imidazoquinoline amines, imidazonaphthyridine amines, imidazotetrahydronaphthyridine amines, oxazoloquinoline amines, thiazoloquinoline amines, oxazolopyridine amines, thiazolopyridine amines, oxazolonaphthyridine amines, thiazolonaphthyridine amines, and 1H-imidazo dimers fused to pyridine amines, quinoline amines, tetrahydroquinoline amines, naphthyridine amines, or tetrahydronaphthyridine amines, are provided. In one embodiment, the aqueous formulations are advantageous for treatment and/or prevention of allergic rhinitis, viral infections, sinusitis, and asthma. For example, N-[2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl]methanesulfonamide (IRM 1) was prepared as a 0.375% aqueous solution
capable of being nasally administered via a spray pump. The solution contained IRM 1 0.375%, CM-cellulose sodium 0.1%, benzalkonium chloride 0.02%, disodium EDTA 0.1%, L-lactic acid 1.53%, PEG 400 15%, 1N NaOH as needed for pH 4.0, and water to 100%. The IRM 1 solution (50 μL) administered to rats once 4 h before infection with humanized, non-lethal influenza virus, almost completely suppressed the virus. titer.
AN 2005:160991 CAPLUS
DN 142:246181
TI Formulations containing an amine-based immune response modifier

IN Hammerbeck, David M.; Guy, Cynthia A.; Leung, Suzanne S.
PA 3M Innovative Properties Company, USA
SO PCT Int. Appl., 118 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005016275	A2	20050224	WO 2004-US25277	20040805
	WO 2005016275	A3	20050414		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				US 2003-493109P	P 20030805
	AU 2004264336	A1	20050224	AU 2004-264336	20040805
				US 2003-493109P	P 20030805
				WO 2004-US25277	W 20040805
	CA 2534313	A1	20050224	CA 2004-2534313	20040805
				US 2003-493109P	P 20030805
				WO 2004-US25277	W 20040805
	US 20050070460	A1	20050331	US 2004-911800	20040805
				US 2003-493109P	P 20030805
	EP 1651190	A2	20060503	EP 2004-780166	20040805
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
				US 2003-493109P	P 20030805
				WO 2004-US25277	W 20040805
	JP 2007501252	T	20070125	JP 2006-522714	20040805
				US 2003-493109P	P 20030805
				WO 2004-US25277	W 20040805
	US 20070292456	A1	20071220	US 2006-595049	20060118
				US 2003-493109P	P 20030805
				WO 2004-US25277	W 20040805

PATENT FAMILY INFORMATION:

FAN	2005:158509				
	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005016273	A2	20050224	WO 2004-US25241	20040805
	WO 2005016273	A3	20051229		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,				

EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

				US 2003-493109P	P	20030805
AU 2004264330	A1	20050224		AU 2004-264330		20040805
				US 2003-493109P	P	20030805
				WO 2004-US25241	W	20040805
CA 2534625	A1	20050224		CA 2004-2534625		20040805
				US 2003-493109P	P	20030805
				WO 2004-US25241	W	20040805
US 20050070460	A1	20050331		US 2004-911800		20040805
				US 2003-493109P	P	20030805
EP 1651216	A2	20060503		EP 2004-780131		20040805
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR						
				US 2003-493109P	P	20030805
				WO 2004-US25241	W	20040805
CN 1852711	A	20061025		CN 2004-80026603		20040805
				US 2003-493109P	P	20030805
				WO 2004-US25241	W	20040805
JP 2007501251	T	20070125		JP 2006-522709		20040805
				US 2003-493109P	P	20030805
				WO 2004-US25241	W	20040805

IT 845638-60-0
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(solns. containing amine-based immunomodulators)

RN 845638-60-0 CAPLUS

CN 1H-Imidazo[4,5-c]quinoline-1-butanamide, 4-amino-N-methoxy-N-methyl-2-propyl- (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT